{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:32Z","timestamp":1787755892895,"version":"build-2784847793"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13193-025-02272-1","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:59:09Z","timestamp":1741751949000},"page":"1605-1623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The INDEPSO-ISPSM Consensus on Peritoneal Malignancies\u2014Diagnosis and Management of Peritoneal Mesothelioma"],"prefix":"10.1007","volume":"16","author":[{"given":"Ambarish","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin K.","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Garach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninad","family":"Katdare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukurdipi","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somashekhar","family":"SP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"6","key":"2272_CR1","first-page":"935","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J (2009) Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control CCC 20(6):935\u2013944","journal-title":"Cancer Causes Control CCC"},{"issue":"1","key":"2272_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/cancers15010229","volume":"15","author":"L Calthorpe","year":"2022","unstructured":"Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K et al (2022) Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States. Cancers (Basel) 15(1):229. https:\/\/doi.org\/10.3390\/cancers15010229","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2272_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/000313480106701019","volume":"67","author":"BW Loggie","year":"2001","unstructured":"Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67(10):999\u20131003","journal-title":"Am Surg"},{"issue":"1","key":"2272_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh IHJT et al (2021) Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 47(1):36\u201359","journal-title":"Eur J Surg Oncol"},{"key":"2272_CR5","doi-asserted-by":"publisher","unstructured":"Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, Bharat A, et al (2023) Mesothelioma: peritoneal, Version 2.2023, NCCN clinical practice guidelines in oncology.\u00a0J Natl Compr Cancer Netw\u00a021(9):961\u2013979. Retrieved Aug 14, 2024, from\u00a0https:\/\/doi.org\/10.6004\/jnccn.2023.0045","DOI":"10.6004\/jnccn.2023.0045"},{"issue":"15","key":"2272_CR6","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer Oxf Engl 49(15):3140\u20133148","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"14","key":"2272_CR7","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol Off J Am Soc Clin Oncol 21(14):2636\u20132644","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2272_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20(4):1093\u20131100","journal-title":"Ann Surg Oncol"},{"key":"2272_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G et al (2016) French Network for Rare Peritoneal Malignancies (RENAPE). Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 65:69\u201379","journal-title":"Eur J Cancer"},{"issue":"5","key":"2272_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12032-018-1125-4","volume":"35","author":"SA Naffouje","year":"2018","unstructured":"Naffouje SA, Tulla KA, Salti GI (2018) The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. Med Oncol Northwood Lond Engl 35(5):69","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"1","key":"2272_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1245\/s10434-023-13640-y","volume":"31","author":"A Chatterjee","year":"2024","unstructured":"Chatterjee A, Kusamura S, Baratti D, Guaglio M, Battaglia L, Deraco M (2024) Impact of perioperative systemic chemotherapy on survival for patients who have diffuse malignant peritoneal mesothelioma treated with CRS-HIPEC. Ann Surg Oncol 31(1):556\u2013566","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2272_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5588\/pha.24.0003","volume":"14","author":"R Singh","year":"2024","unstructured":"Singh R, Frank AL (2024) Analysis of mesothelioma cases and National Cancer Registry data to assess asbestos exposure in India. Public Health Action 14(1):30\u201333. https:\/\/doi.org\/10.5588\/pha.24.0003","journal-title":"Public Health Action"},{"key":"2272_CR13","doi-asserted-by":"publisher","first-page":"100356","DOI":"10.1016\/j.lansea.2024.100356","volume":"21","author":"E Saji","year":"2024","unstructured":"Saji E, Mathew A (2024) Legislation on cancer notification in India: current status. Lancet Reg Health Southeast Asia 21:100356. https:\/\/doi.org\/10.1016\/j.lansea.2024.100356","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"2272_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00001648-199407000-00015","volume":"5","author":"T Sinks","year":"1994","unstructured":"Sinks T et al (1994) A case-control study of mesothelioma and employment in the Hawaii sugarcane industry. Epidemiology 5:466\u2013468","journal-title":"Epidemiology"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ejca.2008.11.032","volume":"45","author":"F Bray","year":"2009","unstructured":"Bray F, Parkin DM (2009) Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45:747\u2013755","journal-title":"Eur J Cancer"},{"key":"2272_CR16","doi-asserted-by":"publisher","unstructured":"Deraco M et al\u00a0(2020) Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. In: Glehen O, Bhatt A (eds) Pathology of Peritoneal Metastases. Springer, Singapore. https:\/\/doi.org\/10.1007\/978-981-15-3773-8_6","DOI":"10.1007\/978-981-15-3773-8_6"},{"key":"2272_CR17","doi-asserted-by":"publisher","unstructured":"Patel S, Sukumar V, P SS et al (2024) The INDEPSO-ISPSM consensus on peritoneal malignancies\u2014methodology. Indian J Surg Oncol. https:\/\/doi.org\/10.1007\/s13193-024-02118-2","DOI":"10.1007\/s13193-024-02118-2"},{"key":"2272_CR18","doi-asserted-by":"crossref","unstructured":"Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S (2013) Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 66(10):847\u201353","DOI":"10.1136\/jclinpath-2012-201303"},{"issue":"11","key":"2272_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ejso.2009.04.007","volume":"35","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Deraco M (2009) Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 35(11):1198\u20131199","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2272_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","volume":"20","author":"NP Schaub","year":"2013","unstructured":"Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS et al (2013) A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 20(2):555\u2013561","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2272_CR21","first-page":"59","volume":"52","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL (2009) Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg 52(1):59\u201364","journal-title":"Can J Surg"},{"issue":"6","key":"2272_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","volume":"44","author":"F Bruno","year":"2018","unstructured":"Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C et al (2018) Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol J 44(6):792\u2013798","journal-title":"Eur J Surg Oncol J"},{"issue":"4","key":"2272_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/cncr.20836","volume":"103","author":"TD Yan","year":"2005","unstructured":"Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103(4):839\u2013849","journal-title":"Cancer"},{"issue":"1","key":"2272_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2005.09.016","volume":"32","author":"E de Bree","year":"2006","unstructured":"de Bree E, Koops W, Kr\u00f6ger R, van Ruth S, Verwaal VJ, Zoetmulder FAN (2006) Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 32(1):65\u201371","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"2272_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","volume":"22","author":"RN Low","year":"2015","unstructured":"Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22(5):1708\u20131715","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2272_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","volume":"16","author":"JL Koh","year":"2009","unstructured":"Koh JL, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16(2):327\u2013333","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2272_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2019.02.030","volume":"47","author":"RN Low","year":"2021","unstructured":"Low RN, Barone RM, Rousset P (2021) Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur J Surg Oncol 47(1):65\u201374","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2272_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/MNM.0000000000000649","volume":"38","author":"J Dubreuil","year":"2017","unstructured":"Dubreuil J, Giammarile F, Rousset P, Rubello D, Bakrin N, Passot G, Isaac S, Glehen O, Skanjeti A (2017) The role of 18F-FDG-PET\/ceCT in peritoneal mesothelioma. Nucl Med Commun 38(4):312\u2013318","journal-title":"Nucl Med Commun"},{"issue":"1","key":"2272_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11547-016-0682-x","volume":"122","author":"A Laghi","year":"2017","unstructured":"Laghi A, Bellini D, Rengo M et al (2017) Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med 122(1):1\u201315. https:\/\/doi.org\/10.1007\/s11547-016-0682-x","journal-title":"Radiol Med"},{"issue":"5","key":"2272_CR30","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","volume":"23","author":"S Kusamura","year":"2016","unstructured":"Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468\u20131473","journal-title":"Ann Surg Oncol"},{"key":"2272_CR31","doi-asserted-by":"crossref","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al (2009)\u00a0Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol Off J Am Soc Clin Oncol 27(36):6237\u201342","DOI":"10.1200\/JCO.2009.23.9640"},{"issue":"1","key":"2272_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","volume":"142","author":"AN Husain","year":"2018","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142(1):89\u2013108. https:\/\/doi.org\/10.5858\/arpa.2017-0124-RA","journal-title":"Arch Pathol Lab Med"},{"key":"2272_CR33","doi-asserted-by":"publisher","unstructured":"Chapel DB, Schulte JJ, Husain AN, Krausz T (2020) Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res. (Suppl 1):S3-S27. https:\/\/doi.org\/10.21037\/tlcr.2019.11.29.","DOI":"10.21037\/tlcr.2019.11.29"},{"key":"2272_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/PAP.0000000000000387","volume":"30","author":"A Malpica","year":"2023","unstructured":"Malpica A (2023) Peritoneal mesothelioma-an update. Adv Anat Pathol 30:262\u2013274","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"2272_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00464-003-9139-0","volume":"18","author":"U Denzer","year":"2004","unstructured":"Denzer U, Hoffmann S, Helmreich-Becker I, Kauczor HU, Thelen M, Kanzler S et al (2004) Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. Surg Endosc 18(7):1067\u20131070","journal-title":"Surg Endosc"},{"issue":"2","key":"2272_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s13193-015-0486-9","volume":"7","author":"RA Seshadri","year":"2016","unstructured":"Seshadri RA, Hemanth Raj E (2016) Diagnostic laparoscopy in the pre-operative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies. Indian J Surg Oncol 7(2):230\u2013235","journal-title":"Indian J Surg Oncol"},{"issue":"2","key":"2272_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/bjs.8908","volume":"100","author":"LH Iversen","year":"2013","unstructured":"Iversen LH, Rasmussen PC, Laurberg S (2013) Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 100(2):285\u2013292","journal-title":"Br J Surg"},{"issue":"6","key":"2272_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/bjs.10723","volume":"105","author":"G Passot","year":"2018","unstructured":"Passot G, Dumont F, Go\u00e9r\u00e9 D, Arvieux C, Rousset P, Regimbeau JM et al (2018) Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE). Br J Surg 105(6):663\u2013667","journal-title":"Br J Surg"},{"issue":"1","key":"2272_CR39","first-page":"187","volume":"23","author":"B Laterza","year":"2009","unstructured":"Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M (2009) Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. Vivo Athens Greece 23(1):187\u2013190","journal-title":"Vivo Athens Greece"},{"issue":"5","key":"2272_CR40","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT et al (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22(5):1686\u20131693","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2272_CR41","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander","year":"2013","unstructured":"Alexander HR, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS et al (2013) Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153(6):779\u2013786","journal-title":"Surgery"},{"issue":"7","key":"2272_CR42","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00423-022-02594-6","volume":"407","author":"M Acs","year":"2022","unstructured":"Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P (2022) Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg 407(7):3057\u20133067","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"2272_CR43","first-page":"9","volume":"69","author":"M Robella","year":"2014","unstructured":"Robella M, Vaira M, Mellano A, Marsanic P, Cinquegrana A, Borsano A et al (2014) Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir 69(1):9\u201315","journal-title":"Minerva Chir"},{"issue":"5","key":"2272_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","volume":"19","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M (2012) Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 19(5):1416\u20131424","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"2272_CR45","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1245\/s10434-020-09232-9","volume":"27","author":"D Roife","year":"2020","unstructured":"Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A et al (2020) CRS\/HIPEC with major organ resection in peritoneal mesothelioma does not impact major complications or overall survival: a retrospective cohort study of the US HIPEC collaborative. Ann Surg Oncol 27(13):4996\u20135004","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2272_CR46","first-page":"948","volume":"32","author":"TD Yan","year":"2006","unstructured":"Yan TD, Yoo D, Sugarbaker PH (2006) Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 32(9):948\u2013953","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"2272_CR47","doi-asserted-by":"publisher","unstructured":"Malgras B, Gayat E, Aoun O\u00a0et al\u00a0(2018)Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study.\u00a0Ann Surg Oncol\u00a025:3271. https:\/\/doi.org\/10.1245\/s10434-018-6631-2","DOI":"10.1245\/s10434-018-6631-2"},{"issue":"12","key":"2272_CR48","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1245\/s10434-023-13973-8","volume":"30","author":"V Kepenekian","year":"2023","unstructured":"Kepenekian V, Sgarbura O, Marchal F, Villeneuve L, Kusamura S, Deraco M (2023) 2022 PSOGI consensus on HIPEC regimens for peritoneal malignancies: diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 30(12):7803\u20137813. https:\/\/doi.org\/10.1245\/s10434-023-13973-8","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2272_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1245\/s10434-009-0756-2","volume":"17","author":"D Baratti","year":"2010","unstructured":"Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17(1):45\u201353","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2272_CR50","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","volume":"157","author":"V Verma","year":"2019","unstructured":"Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB 2nd (2019) Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection. J Thorac Cardiovasc Surg 157(2):758-766.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.10.039","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2272_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"30","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 30:375\u2013386","journal-title":"Lancet"},{"key":"2272_CR52","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19934","volume":"4","author":"K Raghav","year":"2021","unstructured":"Raghav K, Liu S, Overman M et al (2021) Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open 4:e2119934","journal-title":"JAMA Netw Open"},{"key":"2272_CR53","doi-asserted-by":"publisher","unstructured":"Mansfield A & Goodrich et al (2023) Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001). J Clin Oncol 41. TPS8603-TPS8603. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8603.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8603"},{"issue":"7","key":"2272_CR54","first-page":"1228","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D (2017) Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(7):1228\u20131235","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"2272_CR55","first-page":"1","volume":"2012","author":"L Bijelic","year":"2021","unstructured":"Bijelic L, Stuart OA, Sugarbaker P (2021) Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract 2012:1\u20136","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"2272_CR56","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1245\/s10434-017-6033-x","volume":"24","author":"F Le Roy","year":"2017","unstructured":"Le Roy F, Gelli M, Hollebecque A, Honor\u00e9 C, Boige V, Dartigues P et al (2017) Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol 24(12):3640\u20133646","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2272_CR57","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1245\/s10434-021-10983-2","volume":"29","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, P\u00e9ron J, You B, Bonnefoy I, Villeneuve L, Alyami M et al (2022) Non-resectable malignant peritoneal mesothelioma treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a cohort study. Ann Surg Oncol 29(3):2104\u20132113","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2272_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","volume":"18","author":"U Giger-Pabst","year":"2018","unstructured":"Giger-Pabst U, Demtr\u00f6der C, Falkenstein TA, Ouaissi M, G\u00f6tze TO, Rezniczek GA et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 18(1):442","journal-title":"BMC Cancer"},{"key":"2272_CR59","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F et al (2019) Pressurized intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20:e368\u2013e377","journal-title":"Lancet Oncol"},{"issue":"2","key":"2272_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","volume":"16","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M (2009) Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 16(2):463\u2013472","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2272_CR61","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","volume":"22","author":"C Ihemelandu","year":"2015","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH (2015) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol 22(5):1680\u20131685","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2272_CR62","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1245\/s10434-019-07218-w","volume":"26","author":"HA Choudry","year":"2019","unstructured":"Choudry HA, Bednar F, Shuai Y, Jones HL, Pai RK, Pingpank JF et al (2019) Repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion is feasible and offers survival benefit in select patients with peritoneal metastases. Ann Surg Oncol 26(5):1445\u20131453","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2272_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jso.23356","volume":"108","author":"TC Chua","year":"2013","unstructured":"Chua TC, Quinn LE, Zhao J, Morris DL (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol 108(2):81\u201388. https:\/\/doi.org\/10.1002\/jso.23356","journal-title":"J Surg Oncol"},{"issue":"4","key":"2272_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3892\/mco.2023.2627","volume":"18","author":"S Alaklabi","year":"2023","unstructured":"Alaklabi S, Roy AM, Skitzki JJ, Iyer R (2023) Immunotherapy in malignant peritoneal mesothelioma (Review). Mol Clin Oncol 18(4):31. https:\/\/doi.org\/10.3892\/mco.2023.2627","journal-title":"Mol Clin Oncol"},{"key":"2272_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405\u20131414","journal-title":"Lancet"},{"key":"2272_CR66","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C et al (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomized, phase 3 trial. Lancet Oncol 22:1530\u20131540","journal-title":"Lancet Oncol"},{"key":"2272_CR67","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","volume":"9","author":"CJ De Gooijer","year":"2021","unstructured":"De Gooijer CJ, van der Noort V, Stigt JA et al (2021) Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): An investigator-initiated, randomized, open-label, phase 2 trial. Lancet Respir Med 9:585\u2013592","journal-title":"Lancet Respir Med"},{"key":"2272_CR68","doi-asserted-by":"publisher","unstructured":"Fennell DA, Casbard A, Porter C et al (2021) A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant mesothelioma. J Clin Oncol 39:2021 (suppl 15; abstr 8507). https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507"},{"key":"2272_CR69","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M et al (2021) (2021): Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): A randomized, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 22:1438\u20131447","journal-title":"Lancet Oncol"},{"issue":"6","key":"2272_CR70","doi-asserted-by":"publisher","first-page":"e843","DOI":"10.1200\/OP.21.00785","volume":"18","author":"HL Kindler","year":"2022","unstructured":"Kindler HL (2022) Systemic therapy for mesothelioma: turning the corner. JCO Oncol Pract 18(6):e843\u2013e845. https:\/\/doi.org\/10.1200\/OP.21.00785","journal-title":"JCO Oncol Pract"},{"issue":"Suppl 1","key":"2272_CR71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s13193-022-01691-8","volume":"14","author":"P Kammar","year":"2023","unstructured":"Kammar P, Garach N, Bhatt A, Anam J, Maniar V, Gore A, Mehta S (2023) High-risk peritoneal mesothelioma: does metronomic chemotherapy have a role? Indian J Surg Oncol 14(Suppl 1):181\u2013188. https:\/\/doi.org\/10.1007\/s13193-022-01691-8","journal-title":"Indian J Surg Oncol"},{"issue":"5","key":"2272_CR72","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11605-022-05540-5","volume":"27","author":"AD Rouhi","year":"2023","unstructured":"Rouhi AD, Choudhury RA, Hoeltzel GD, Yule A, Williams NN, Dumon KR, Karakousis GC (2023) Delayed CRS-HIPEC is associated with decreased survival in patients with malignant peritoneal mesothelioma: a Markov decision analysis. J Gastrointest Surg 27(5):995\u2013997","journal-title":"J Gastrointest Surg"},{"key":"2272_CR73","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D et al (2011) A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 117:1855\u20131863. https:\/\/doi.org\/10.1002\/cncr.25640","journal-title":"Cancer"},{"issue":"3","key":"2272_CR74","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejso.2022.10.003","volume":"49","author":"JP van Kooten","year":"2023","unstructured":"van Kooten JP, de Gooijer CJ, von der Th\u00fcsen JH, Brandt-Kerkhof ARM, Albers AGJ, Lahaye MJ, Monkhorst K et al (2023) Impact of centralization of care for malignant peritoneal mesothelioma: a historical cohort study from the Dutch mesothelioma expert centers. Eur J Surg Oncol 49(3):611\u2013618. https:\/\/doi.org\/10.1016\/j.ejso.2022.10.003","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"2272_CR75","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, Bhatt A, P\u00e9ron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O (2022) Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 19(11):698\u2013718. https:\/\/doi.org\/10.1038\/s41571-022-00675-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"2272_CR76","doi-asserted-by":"publisher","unstructured":"Sayyed R, Khan F, Brandl A, Niazi S (2020) Case selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy; our experience from peritoneal MDT. Eur J Surg Oncol 48(2):E-162. https:\/\/doi.org\/10.1016\/j.ejso.2019.11.429","DOI":"10.1016\/j.ejso.2019.11.429"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-025-02272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-025-02272-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-025-02272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T21:02:24Z","timestamp":1765918944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-025-02272-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s13193-025-02272-1","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}